RANKL inhibition with denosumab does not influence 3-year progression of aortic calcification or incidence of adverse cardiovascular events in postmenopausal women with osteoporosis and high cardiovascular risk - Samelson, E J; Miller, P D; Christiansen, C (J Bone Miner Res, 2014)
, et al.